FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a recovered caninized antibody or its antigen-binding fragment, which specifically binds to canine CTLA-4. Also disclosed is a nucleic acid coding said antibody; an expression vector, a host cell containing said nucleotide acid; pharmaceutical composition containing said antibody. Disclosed is a method of increasing activity of immunocyte using said antibody; method of producing said antibody.
EFFECT: invention makes it possible to effectively treat a malignant tumour.
12 cl, 5 dwg, 5 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| PEPTIDE VACCINES AGAINST INTERLEUKIN-31 | 2019 |
|
RU2786441C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
